The Market may be explored by technology as ELISA, Chemiluminescence Immunoassay (CLIA), and Enzyme
Immunoassay (EIA), Nucleic Acid Amplification Test (NAT), Western Blotting, and Next-Generation Sequencing
(NGS). The NAT may be further split into real-time PCR and transcription-mediated amplification (TMA). The
“NAT” dominated the blood screening market in 2016 and is anticipated to maintain its dominance by 2024 due
to growing number of blood donations, increasing occurrence of transferrable diseases, and growing disposable
income with respect to reimbursement for NAT-tested blood. Furthermore, the increasing consciousness about
advanced and innovative applications of NAT in disease screening and the growing demand for safe donated
blood by patients suffering from thalassemia, hemophilia, and sickle-cell anemia boost the development of this
technology sector. Blood Screening Market may be explored by product outlook as Reagent& kit, and
Instrument.
The market may be analyzed based on end user into Blood Banks, and Hospitals. The “blood banks” segment
dominated the market in 2016 and anticipated to maintain its dominance by 2024 due to factors such as growing
demand for donated blood, rising number of rising awareness regarding the safety of blood, organ
transplantation surgeries, growing number of donations worldwide, and development in government funding
to charitable trusts.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/blood-screening-market
North America accounted for the major share of the global Blood Screening Industry in 2016 and will continue
to lead in the forecast period due to factors such as growing participation of several government associations in
screening & transfusion activities and blood donations, and rising adoption of nucleic acid tests (NAT).
Some of the key players that fuel the growth of the Blood Screening Market include Becton, Danaher
Corporation, Abbott Laboratories, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc, F. Hoffmann-La Roche Ltd,
Grifols, Dickinson and Company, Ortho Clinical Diagnostics, Siemens AG, and Thermo Fisher Scientific Inc. The
leading companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost
the inorganic growth of the industry.
Market Segment:
Blood Screening Technology Outlook (Market Revenue in USD Million, 2013 - 2024)
• Nucleic Acid Amplification Test (NAT)
• ELISA
• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
• Next-Generation Sequencing (NGS)
• Western Blotting